Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

X-chromosome upregulation operates on a gene-by-gene basis at transcriptional and translational levels [ChIP-seq]

ABSTRACT: Female (XX) mice undergo both X-chromosome inactivation (XCI) and X-chromosome upregulation (XCU) to balance X-linked gene dosage with male (XY) mice and autosomes. XCU has also been reported in XY cells, as well as cells with X-chromosome monosomy (XO). The two X-dosage compensation processes have been shown to occur simultaneously; as one X-chromosome is inactivated, the remaining active X-chromosome becomes upregulated. However, it remains unknown if cells sense and adapt gene dosage at the chromosomal level or on a gene-by-gene basis. Here, we demonstrate that mouse embryonic stem cells can compensate gene dosage by XCU when specific regions or genes are deleted. Compensation occurs at both transcriptional and protein levels and on a gene-by-gene basis. Moreover, we provide evidence for autosomal gene dosage compensation in trans. Overall, our findings demonstrate that mammalian cells can sense heterozygous deletions or inactivation of specific chromosome regions or genes and can compensate in a gene-specific manner at the transcriptional or protein level. These results have important implications for understanding the evolution of gene dosage compensation and its relevance to health, and disease.

ORGANISM(S): Mus musculus

PROVIDER: GSE282785 | GEO | 2025/06/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

X-chromosome upregulation operates on a gene-by-gene basis at transcriptional and translational levels [scRNA-seq]

Project description:Female (XX) mice undergo both X-chromosome inactivation (XCI) and X-chromosome upregulation (XCU) to balance X-linked gene dosage with male (XY) mice and autosomes. XCU has also been reported in XY cells, as well as cells with X-chromosome monosomy (XO). The two X-dosage compensation processes have been shown to occur simultaneously; as one X-chromosome is inactivated, the remaining active X-chromosome becomes upregulated. However, it remains unknown if cells sense and adapt gene dosage at the chromosomal level or on a gene-by-gene basis. Here, we demonstrate that mouse embryonic stem cells can compensate gene dosage by XCU when specific regions or genes are deleted. Compensation occurs at both transcriptional and protein levels and on a gene-by-gene basis. Moreover, we provide evidence for autosomal gene dosage compensation in trans. Overall, our findings demonstrate that mammalian cells can sense heterozygous deletions or inactivation of specific chromosome regions or genes and can compensate in a gene-specific manner at the transcriptional or protein level. These results have important implications for understanding the evolution of gene dosage compensation and its relevance to health, and disease.

2025-06-19 | GSE282790 | GEO

X-chromosome upregulation operates on a gene-by-gene basis at transcriptional and translational levels [RNA-seq]

2025-06-19 | GSE282784 | GEO

Segmental X-chromosome monosomies are compensated by transcriptional upregulation.

Project description:XX mice undergo both X-chromosome inactivation (XCI) and X-chromosome upregulation (XCU) to balance X-linked gene dosage with autosomes and XY mice. XCU has also been reported in XY cells, as well as cells with a single copy of the X-chromosome (XO). The two dosage compensation processes have been shown to occur simultaneously; as one X-chromosome is inactivated, the remaining active X-chromosome becomes upregulated. However, it remains unknown if cells sense and adapt gene dosage at the chromosomal level, or on a gene-by-gene basis. Here, we demonstrate that mouse embryonic stem cells can compensate gene dosage by XCU when specific regions or genes are deleted. Compensation occurs at both the transcriptional and protein levels, and on a gene-by-gene basis. Moreover, we provide evidence for autosomal gene dosage compensation in trans. Overall, our results demonstrate that mammalian cells can sense when specific chromosome regions or genes are heterozygously deleted or inactivated, and can compensate at the transcriptional or protein level with gene specificity. Our results have important implications for our understanding of the evolution of gene dosage compensation, health, and disease.

2025-06-19 | PXD057399 | Pride

Dosage compensation mass spectrometry in platypus, chicken and mouse

Project description:Gene dosage imbalance of heteromorphic sex chromosomes (XY or ZW) exists between the sexes, and with the autosomes. Mammalian X chromosome inactivation was long thought to imply a critical need for dosage compensation in vertebrates. However, mRNA abundance measurements that demonstrated sex chromosome transcripts are neither balanced between the sexes or with autosomes in monotreme mammals or birds brought sex chromosome dosage compensation into question. This study examines transcriptomic and proteomic levels of dosage compensation in platypus and chicken compared to mouse, a model eutherian species. We analyzed mRNA and protein levels in heart and liver tissues of chicken, mouse and platypus.

2024-07-30 | PXD040182 | Pride

RNA stability controlled by m6A methylation contributes to X-to-autosome dosage compensation in mammals

Project description:In mammals, X-chromosomal genes are expressed from a single copy since males (XY) possess a single X chromosome, while females (XX) undergo X inactivation. To compensate for this reduction in dosage compared to two active copies of autosomes, it has been proposed that genes from the active X chromosome exhibit dosage compensation. However, the existence and mechanism of X-to-autosome dosage compensation are still under debate. Here, we show that X-chromosomal transcripts are reduced in m6A modifications and more stable compared to their autosomal counterparts. Acute depletion of m6A selectively stabilises autosomal transcripts, resulting in perturbed dosage compensation in mouse embryonic stem cells. We propose that higher stability of X-chromosomal transcripts is directed by lower levels of m6A, indicating that mammalian dosage compensation is partly regulated by epitranscriptomic RNA modifications.

| EGAS00001007112 | EGA

d5080ccf-6024-42b1-ae2f-e1770fa19cf9 - samples

| EGAD00001010194 | EGA

RNA stability controlled by m6A methylation provides X to autosome compensation in mammals [RNA-seq]

Project description:In therian mammals, X-chromosomal genes are expressed only from a single active X chromosome, both in males (XY) as well as females (XX). To compensate for this reduction in dosage compared to the evolutionary ancestral state on two autosomes, it has been proposed that genes from the active X chromosome exhibit dosage compensation (“Ohno’s hypothesis”). However, the existence and mechanism of X-to-autosome dosage compensation are still under debate. Here, we show that dosage compensation is achieved via differential N6-methyladenosine (m6A) RNA modification. X-chromosomal transcripts are reduced in m6A modifications and more stable compared to the autosomal counterparts. Acute depletion of m6A using a small molecule inhibitor differentially affects autosomal and X-chromosomal transcripts across sexes, cell types, tissues and species, resulting in perturbed dosage compensation. We propose that higher stability of X-chromosomal transcripts is directed by lower levels of m6A, indicating that mammalian dosage compensation occurs via epitranscriptomic RNA regulation.

2023-02-14 | GSE203642 | GEO